Literature DB >> 10503879

Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence.

J H Martin1, O Alalami, H W van den Berg.   

Abstract

We have recently reported the presence of inducible nitric oxide synthase (iNOS) in the human breast cancer cell line ZR-75-1. The purpose of the present study was to examine differences in expression of endothelial (eNOS) and inducible nitric oxide synthase in normal human mammary epithelial cells (HMEC) compared with two variants of the ZR-75-1 cell line. One variant has acquired estrogen independence, the other has acquired resistance to tamoxifen. Immunohistochemical investigations demonstrated that 100% of HMEC cells staining positive for both eNOS and iNOS. ZR-75-1 cells showed 100% staining for eNOS and 52% positive staining for iNOS. There was no difference in staining between the parent cell line and cells which had acquired resistance to tamoxifen (ZR-75-9a1). However, in the breast cancer cell line which had acquired estrogen independence (ZR-PR-LT), less than 5% of cells exhibited positive staining for eNOS and staining for iNOS was undetectable. L-Arginine increased NO production in both ZR-75-9a1 and ZR-PR-LT cells. Progesterone was able to down regulate NO production in both ZR-75-1 and ZR-75-9a1 cells and this effect was reversible by RU486. These results support the suggestion that loss of NOS expression may be associated with the progression of breast cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10503879     DOI: 10.1016/s0304-3835(99)00198-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Therapeutic efficacy of Kalpaamruthaa on reactive oxygen/nitrogen species levels and antioxidative system in mammary carcinoma bearing rats.

Authors:  Krishnamurthi Veena; Palanivelu Shanthi; Panchanatham Sachdanandam
Journal:  Mol Cell Biochem       Date:  2006-08-08       Impact factor: 3.396

Review 2.  NO to breast: when, why and why not?

Authors:  Shehla Pervin; Gautam Chaudhuri; Rajan Singh
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

3.  Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells.

Authors:  Zhila Khalkhali-Ellis; Mary J C Hendrix
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.

Authors:  G M K Tse; F C Wong; A K H Tsang; C S Lee; P C W Lui; A W I Lo; B K B Law; R A Scolyer; R Z Karim; T C Putti
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

5.  Estrogen-induced apoptosis of breast epithelial cells is blocked by NO/cGMP and mediated by extranuclear estrogen receptors.

Authors:  Irida Kastrati; Praneeth D Edirisinghe; Gihani T Wijewickrama; Gregory R J Thatcher
Journal:  Endocrinology       Date:  2010-10-13       Impact factor: 4.736

Review 6.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

7.  Nitrotyrosine, inducible nitric oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) are increased in thyroid tumors from children and adolescents.

Authors:  A Patel; C Fenton; R Terrell; P A Powers; C Dinauer; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

8.  Dynamic interplay between nitration and phosphorylation of tubulin cofactor B in the control of microtubule dynamics.

Authors:  Suresh K Rayala; Emil Martin; Iraida G Sharina; Poonam R Molli; Xiaoping Wang; Raymond Jacobson; Ferid Murad; Rakesh Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-28       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.